Navigation Links
Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
Date:11/12/2012

WESTFORD, Mass., Nov. 12, 2012 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) (the "Company"), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that it has commenced an underwritten registered public offering of 2,600,000 shares of its class A common stock. In addition, El.En. S.p.A. is offering 600,000 shares of the Company's class A common stock.

Leerink Swann LLC, the underwriter for this offering, has the option for a period of up to 30 days from the date of the prospectus supplement to purchase up to an additional 240,000 shares from the Company and up to an additional 240,000 shares from El.En. S.p.A. at the public offering price less underwriting discounts and commissions.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.

The Company intends to use the net proceeds from the shares sold by it in this offering for general corporate purposes and to fund its potential acquisition of complementary products, technologies or businesses. The Company will not receive any proceeds from the sale of the shares by El.En. S.p.A.

The shares are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC") and declared effective on October 26, 2012.  A preliminary prospectus supplement and accompanying base prospectus related to the offering will be filed with the SEC and available on the SEC's website at http://www.sec.gov.  Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (8
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... June 20, Actelion Ltd (SWX: ATLN) announced today ... mildly symptomatic pulmonary,arterial hypertension (PAH) patients (WHO functional ... clinical deterioration by significantly,delaying time to clinical worsening ... FC III/IV. A significant reduction in pulmonary vascular,resistance ...
... PXS; Nasdaq: PXSL) today announced that the company ... reached agreement on the phase 3,registration trial of ... The SPA process allows for FDA evaluation ... primary basis of an efficacy claim in support ...
Cached Medicine Technology:Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 2Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 3Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 4Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 5Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 6Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3
(Date:8/20/2014)... Research has been chosen by Plymouth University to be ... in April 2009 to raise awareness of, and funding ... for brain tumour patients. , A range of events ... for the charity, and members of staff and students, ... to donate, fundraise and volunteer. The involvement of the ...
(Date:8/20/2014)... Boston, MA (PRWEB) August 20, 2014 Fresh ... new jogging stroller just sprung from the starting blocks. , ... design studios, has added the Urbini Avi jogger ... for nearly a year, with a look inspired by the ... and delight fitness-minded parents. , This versatile jogger offers a ...
(Date:8/20/2014)... 20, 2014 Parents and kids across ... from summer months means buying textbooks and arranging after ... often a forgotten part of the annual re-commitment to ... the American Psychological Association, 27% of students say they ... (45%) say they are stressed by school pressures. The ...
(Date:8/20/2014)... 20, 2014 The report “Automotive ... - A Global Analysis: by Geography - Trends ... classifies and defines automotive airbag and seatbelt market ... highlights potential growth opportunities in the coming years ... market drivers, restrains, growth indicators, challenges, legislation trends, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Shepherd Health Care System in Hermiston, Ore. The top ... B. E. Smith has recently placed more than 900 ... Care System is a progressive, not-for-profit healthcare organization serving ...
Breaking Medicine News(10 mins):Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3
... doctors in hospital and general practice are being concerned about a ... that 93% of those with worries had taken some form of ... 10% of GPs and 4% of hospital doctors had taken no ... expressed concerns and even made reference to possible alcohol abuse. ...
... Calcutta Medical College and Hospital expressed their support to ... northern region of the State. West Bengal is ... ,Barring the emergency department, services in the Calcutta ... doctors and interns struck work against the central government's ...
... Dr. Michael Thun of the American Cancer Society it was found ... wee less.// On the other hand men who never smoked had ... among a million Americans. Lung cancer is by far the biggest ... this year in the United States alone. ,This report ...
... moderate exercise regimen for 30-45 minutes, performed on all weekdays ... cancer in women. Breast cancer// is the most common form ... women at some stage of their life in the Western ... achieve early detection and effective treatment, about 20 percent of ...
... scare not yet ascertained the top floors of the Melbourne ... to identify the cause of illnesses.// ,Tests on ... to establish any link as yet to the seven cases ... ,Five of these seven cases were employees who had ...
... to researchers at the University of Pennsylvania and Temple ... important role in diseases of the eye. This is ... covering the eyes.// The researchers, led by Mina ... Institute, and Marcella Macaluso, Ph.D., of the Sbarro Institute ...
Cached Medicine News:Health News:Increase In The Number Of Doctors Reporting About Their Colleagues Abilities 2Health News:Medicos Of The Calcutta Medical College Join Anti-Reservation Quota Protest 2Health News:Moderate Exercise, Key To Breast Cancer Prevention 2Health News:PAI-2 Plays a Pivotal Role in Eye Infections 2
... Pump is a syringe infusion ... the administration of many intravenous ... It provides for the convenient ... and vasoactive drugs through the ...
Developed to meet the infusion needs in NICU, Anesthesia and Critical Care, the AUTO SYRINGE AS50 Infusion Pump delivers precise, controlled infusions....
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
The FLO-GARD 6201 Volumetric Infusion Pump and the FLO-GARD 6301 Dual-Channel Volumetric Infusion Pump are industry standard in standard set infusion pump technology....
Medicine Products: